| 汪 建,王兴远,周 伟,陈朝辉,江 波.埃克替尼治疗晚期非小细胞肺癌的疗效及对患者血清相关指标水平的影响[J].,2017,17(19):3738-3741 |
| 埃克替尼治疗晚期非小细胞肺癌的疗效及对患者血清相关指标水平的影响 |
| Effects of Icotinib on Treatment of Advanced Non-small Cell Lung Cancer and Serum Levels of Related Indexes |
| 投稿时间：2016-12-19 修订日期：2016-12-30 |
| DOI：10.13241/j.cnki.pmb.2017.19.035 |
| 中文关键词: 晚期非小细胞肺癌 埃克替尼 细胞角蛋白21-1 鳞状细胞癌抗原 血管内皮生长因子 |
| 英文关键词: Advanced non-small cell lung cancer Icotinib Cyfre21-1 SCCA VEGF |
| 基金项目:四川省卫生厅科研项目(050246) |
|
| 摘要点击次数: 359 |
| 全文下载次数: 195 |
| 中文摘要: |
| 摘要 目的：分析埃克替尼对晚期非小细胞肺癌的治疗效果及对血清指标的影响。方法：将86例晚期非小细胞肺癌患者按抽签法分成对照组与观察组，各43例。对照组采用多西他赛治疗，观察组采用埃克替尼治疗。观察并比较两组患者治疗前后血清细胞角蛋白21-1（Cyfre21-1）、鳞状细胞癌抗原（SCCA）、血管内皮生长因子（VEDF）、自然杀伤（NK）细胞、CD4+、CD8+、CD4+/CD8+，白细胞介素-8（IL-8）、肿瘤坏死因子-α（TNF-α）、基质金属蛋白酶-2（MMP-2）及基质金属蛋白酶-9（MMP-9）水平、临床疗效以及安全性。结果：观察组疾病控制率高于对照组，差异具有统计学意义（P<0.05）。治疗后，两组患者血清Cyfre21-1、SCCA、CD8+、LI-8、TNF-α、MMP-2及MMP-9均低于治疗前，且观察组低于对照组，，差异具有统计学意义（P<0.05）；治疗后，两组患者血清VEGF水平均降低，且观察组低于对照组，差异具有统计学意义（P<0.05）；治疗后，两组患者血清NK、CD4+及CD4+/CD8+均高于治疗前，且观察组高于对照组，差异具有统计学意义（P<0.05）；观察组不良反应发生率低于对照组，差异具有统计学意义（P<0.05）。结论：埃克替尼对晚期非小细胞肺癌的临床效果肯定，可下调血清VEGF表达。 |
| 英文摘要: |
| ABSTRACT Objective: To analyze the clinical effect of icotinib on treatment of advanced non-small cell lung cancer and serum in- dex levels. Methods: 86 patients with advanced non-small cell lung cancer were selected and randomly divided into the control group and the observation group with 43 cases in each group. The patients in the control group were treated with docetaxel, while the patients in the observation group were treated with icotinib. Then the serum levels of cytokeratin 21-1 (Cyfre21-1), squamous cell carcinoma antigen (SCCA), natural killer (NK) cells, CD4+, CD8+, CD4+/CD8+, interleukin-8 (IL-8), tumor necrosis factor-α(TNF-α), matrix metallopro- teinase-2 (MMP-2) and matrix metalloproteinases-9 (MMP-9) of patients and the clinical efficacy and security. Results: The disease con- trol rate of observation group was higher than that of the control group, and the difference was statistically significant (P<0.05). After treatment, the serum levels of SCCA, Cyfre21-1, CD8+, LI-8, TNF-α, MMP-2 and MMP-9 in the two groups decreased, and the obser- vation group was lower than that of the control group, and the differences were statistically significant (P<0.05); After treatment, the serum levels of VEGF in the two groups decreased, and the observation group was lower than that of the control group, and the differ- ences were statistically significant (P<0.05); After treatment, the serum levels of NK, CD4+ and CD4+/CD8+ in the two groups increased, and the observation group was higher than that of the control group, and the differences were statistically significant (P<0.05). The ad- verse reactions of the observation group was lower than that of the control group, and the difference was statistically significant (P<0.05). Conclusion: The clinical efficacy of icotinib in the treatment of advanced non - small cell lung cancer can reduce the serum levels of SCCA, Cyfre21-1, CD8+, LI-8, TNF-α, MMP-2 and MMP-9 and increase the NK, CD4+ and CD4+/CD8+ of patients. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
